Compare ARAI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARAI | LEXX |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Canada |
| Employees | 51 | 7 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 16.5M |
| IPO Year | N/A | N/A |
| Metric | ARAI | LEXX |
|---|---|---|
| Price | $0.37 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $1.50 |
| AVG Volume (30 Days) | ★ 491.8K | 60.9K |
| Earning Date | 04-15-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $800.66 | N/A |
| Revenue Next Year | $650.00 | $601.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.46 |
| 52 Week High | $12.85 | $1.55 |
| Indicator | ARAI | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 44.40 |
| Support Level | $0.36 | $0.56 |
| Resistance Level | $0.63 | $0.70 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 21.45 | 24.12 |
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.